Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3β pathway in substantia nigra neurons in Parkinson rats

Zhou, Weia; Chen, Leic; Hu, Xiqinga; Cao, Shanshanb; Yang, Junxiub

doi: 10.1097/WNR.0000000000001149
CLINICAL NEUROSCIENCE

The aim of this study is to investigate the protective effect of epigallocatechin-3-gallate (EGCG) on apoptosis and mTOR/AKT/GSK-3β pathway in substantia nigra neurons in 6-dopamine-induced Parkinson rats. A total of 30 healthy male SD rats were randomly divided into control group, the Parkinson model group, and Parkinson model+EGCG treatment group. The model and EGCG groups were injected into the right striatum with 6-OHDA to establish the Parkinson model, and the control group was injected with saline only. The EGCG group was intragastrically administered with EGCG 50 mg/kg daily for 4 weeks. The rats’ turns, speed, and left forelimb usage; neuron apoptosis by TUNEL; and the α-synuclein protein expression in substantia nigra by immunohistochemical staining were studied. Western blotting was used to detect the relative protein (mTOR, AKT and GSK-3β) expressions. Compared with the model group, the EGCG group significantly reduced the rotation speed; increased the left forelimb usage (P<0.01); reduced the neuron apoptosis (P<0.01); decreased α-synuclein expression (P<0.01); and decreased the mTOR, AKT, and GSK-3β protein expressions (P<0.01). EGCG can reduce neuron cell apoptosis in substantia nigra neurons in 6-OHDA-induced Parkinson rats. The mechanism might be related to mTOR/AKT/GSK-3β activation.

aDepartment of Neurology, Tianjin United Medical Centre

bTianjin University of Traditional Chinese Medicine

cTianjin Huanhu Hospital, Tianjin, China

Correspondence to Lei Chen, MD, Tianjin Huanhu Hospital, No. 6, Jizhao Road, Jinnan District, Tianjin, China Tel/fax: +86 225 906 5906; e-mail: leichene@163.com

Received June 25, 2018

Accepted October 1, 2018

© 2019 Wolters Kluwer Health | Lippincott Williams & Wilkins